← Leaderboards
Raymond T Chung
Massachusetts General Hospital
$38,306,004
Attributed
$56,144,958
Total exposure
28
Grants
21
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.8M · FY2006–25$10M$7.5M$5M$2.5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$99,650,133 · 29
By mechanism
U19$51,547,286 · 9
R01$27,994,550 · 10
T32$9,743,485 · 1
U01$6,002,674 · 2
R56$1,994,744 · 3
K24$1,619,926 · 1
Top collaborators
- Ramnik J Xavier17 shared
- Daryl T Lau15 shared
- E. John Wherry14 shared
- Wolfram Goessling8 shared
- Yujin Hoshida8 shared
- Georg Michael Lauer7 shared
- Arthur Y Kim6 shared
- Wenyu Lin5 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Georg Michael Lauer$24,583,765
- Kenneth D Bloch$14,282,889
- Wenyu Lin$1,772,775
- Randall T Peterson$17,953,472
- Amir Mohareb$543,089
Others in their field
Top investigators on “Hepatitis C Virus”
- Constance Ann Benson · University Of California, San Diego$150,079,712
- Sharon A Nachman · Johns Hopkins University$91,575,784
- Peter B. Gilbert · Fred Hutchinson Cancer Center$77,122,577
- Robert Turner Schooley · University Of Colorado Denver$45,719,253
- Charles R Rinaldo · University Of Pittsburgh At Pittsburgh$44,694,148
- Charles M. Rice · Rockefeller University$42,549,577
Research focus
Hepatitis C VirusViralPersonsResponseImmuneProgramsLiverInfectionBaseChronicLiver DiseasesHepatitis CAntiviral AgentsHepatocyteDisease ProgressionSignal TransductionInterferonsResearch PersonnelCellsVirus DiseasesMediatingAffectCohortReporting
Grant awards (167)
Durable Alteration of the Human Immune system after Infection or Immunotherapy$2,328,551
U19 · FY2025 · AI · contact PI
Trial of Statins for Chemoprevention in Hepatocellular Carcinoma$1,487,531
R01 · FY2025 · CA · contact PI
YAP signaling in the pathogenesis of NAFLD in people living with HIV$812,743
R01 · FY2025 · DK · contact PI
Research Training in Digestive Diseases$725,975
T32 · FY2025 · DK · contact PI
Cooperative mechanisms of HIV-enhanced liver fibrogenesis in HBV Coinfection$709,110
R01 · FY2025 · AI · contact PI
Therapeutic modulation of a proteomic HCC risk signature with statins in patients with liver cirrhosis$628,059
U01 · FY2025 · CA
Core A: Administrative Core$97,708
U19 · FY2025 · AI · contact PI
Durable Alteration of the Human Immune system after Infection or Immunotherapy$2,446,152
U19 · FY2024 · AI · contact PI
Immunologic correlates of functional cure of HBV with immune checkpoint blockade$834,534
R01 · FY2024 · AI
Trial of Statins for Chemoprevention in Hepatocellular Carcinoma$785,064
R01 · FY2024 · CA · contact PI
YAP signaling in the pathogenesis of NAFLD in people living with HIV$780,234
R01 · FY2024 · DK · contact PI
Cooperative mechanisms of HIV-enhanced liver fibrogenesis in HBV Coinfection$709,110
R01 · FY2024 · AI · contact PI
Research Training in Digestive Diseases$627,110
T32 · FY2024 · DK · contact PI
Therapeutic modulation of a proteomic HCC risk signature with statins in patients with liver cirrhosis$323,446
U01 · FY2024 · CA
Core A: Administrative Core$105,973
U19 · FY2024 · AI · contact PI
Research Training in Digestive Diseases$99,227
T32 · FY2024 · DK · contact PI
Impact of Immunotherapy on Viral Immunity in Humans$2,043,956
U19 · FY2023 · AI · contact PI
Immunologic correlates of functional cure of HBV with immune checkpoint blockade$834,534
R01 · FY2023 · AI
YAP signaling in the pathogenesis of NAFLD in people living with HIV$829,042
R01 · FY2023 · DK · contact PI
Research Training in Digestive Diseases$677,154
T32 · FY2023 · DK · contact PI
Therapeutic modulation of a proteomic HCC risk signature with statins in patients with liver cirrhosis$366,710
U01 · FY2023 · CA
Core A: Administrative Core$128,479
U19 · FY2023 · AI · contact PI
Research Training in Digestive Diseases$90,216
T32 · FY2023 · DK · contact PI
Trial of Statins for Chemoprevention in Hepatocellular Carcinoma$1
R01 · FY2023 · CA · contact PI
Impact of Immunotherapy on Viral Immunity in Humans$2,043,956
U19 · FY2022 · AI · contact PI
Immunologic correlates of functional cure of HBV with immune checkpoint blockade$834,534
R01 · FY2022 · AI
Cooperative mechanisms of HIV-enhanced liver fibrogenesis in HBV Coinfection$709,110
R01 · FY2022 · AI · contact PI
Trial of Statins for Chemoprevention in Hepatocellular Carcinoma$697,704
R01 · FY2022 · CA · contact PI
Research Training in Digestive Diseases$682,113
T32 · FY2022 · DK · contact PI
HIV-induced monocyte and macrophage perturbations driving liver fibrogenesis$650,980
R56 · FY2022 · DK
HIV, HCV, Hippo, and Liver Disease Progression$631,145
R01 · FY2022 · AI · contact PI
Core A: Administrative Core$136,836
U19 · FY2022 · AI · contact PI
Research Training in Digestive Diseases$85,553
T32 · FY2022 · DK · contact PI
Impact of Immunotherapy on Viral Immunity in Humans$2,043,956
U19 · FY2021 · AI · contact PI
Impact of Immunotherapy on Viral Immunity in Humans$879,190
U19 · FY2021 · AI · contact PI
Immunologic correlates of functional cure of HBV with immune checkpoint blockade$834,534
R01 · FY2021 · AI
Cooperative mechanisms of HIV-enhanced liver fibrogenesis in HBV Coinfection$709,110
R01 · FY2021 · AI · contact PI
Trial of Statins for Chemoprevention in Hepatocellular Carcinoma$675,855
R01 · FY2021 · CA · contact PI
Research Training in Digestive Diseases$619,932
T32 · FY2021 · DK · contact PI
HIV, HCV, Hippo, and Liver Disease Progression$608,551
R01 · FY2021 · AI · contact PI
Core A: Administrative Core$106,040
U19 · FY2021 · AI · contact PI
Impact of Immunotherapy on Viral Immunity in Humans$2,043,956
U19 · FY2020 · AI · contact PI
Impact of Immunotherapy on Viral Immunity in Humans$1,126,470
U19 · FY2020 · AI · contact PI
Immunologic correlates of functional cure of HBV with immune checkpoint blockade$847,913
R01 · FY2020 · AI
Cooperative mechanisms of HIV-enhanced liver fibrogenesis in HBV Coinfection$709,110
R01 · FY2020 · AI · contact PI
HIV, HCV, Hippo, and Liver Disease Progression$642,162
R01 · FY2020 · AI · contact PI
Research Training in Digestive Diseases$556,040
T32 · FY2020 · DK · contact PI
Core A: Administrative Core$121,898
U19 · FY2020 · AI · contact PI
Impact of Immunotherapy on Viral Immunity in Humans$2,043,956
U19 · FY2019 · AI · contact PI
HIV, HCV, Hippo, and Liver Disease Progression$714,134
R01 · FY2019 · AI · contact PI
Research Training in Digestive Diseases$587,877
T32 · FY2019 · DK · contact PI
Harvard Hepatitis B Consortium$371,677
U01 · FY2019 · DK
HIV-Associated Macrophage Alterations and Progressive Liver Disease$325,001
R01 · FY2019 · DK · contact PI
Harvard Hepatitis B Consortium$127,225
U01 · FY2019 · DK
Core A: Administrative Core$114,586
U19 · FY2019 · AI · contact PI
Reversal of Immune Failure with Viral Cure in Chronic HCV Infection$2,277,111
U19 · FY2018 · AI · contact PI
HIV, HCV, Hippo, and Liver Disease Progression$792,339
R01 · FY2018 · AI · contact PI
Research Training in Digestive Diseases$575,258
T32 · FY2018 · DK · contact PI
Restoration of Innate Immunity with Viral Cure$509,289
U19 · FY2018 · AI · contact PI
Harvard Hepatitis B Consortium$396,375
U01 · FY2018 · DK
HIV-Associated Macrophage Alterations and Progressive Liver Disease$325,001
R01 · FY2018 · DK · contact PI
Administrative Core$173,225
U19 · FY2018 · AI · contact PI
Harvard Hepatitis B Consortium$127,225
U01 · FY2018 · DK
Pilot/Feasibility Studies Program$84,249
U19 · FY2018 · AI · contact PI
Research Training in Digestive Diseases$73,848
T32 · FY2018 · DK · contact PI
Reversal of Immune Failure with Viral Cure in Chronic HCV Infection$2,277,110
U19 · FY2017 · AI · contact PI
Research Training in Digestive Diseases$548,234
T32 · FY2017 · DK · contact PI
Restoration of Innate Immunity with Viral Cure$522,953
U19 · FY2017 · AI · contact PI
Harvard Hepatitis B Consortium$353,345
U01 · FY2017 · DK
HIV-Associated Macrophage Alterations and Progressive Liver Disease$325,000
R01 · FY2017 · DK · contact PI
Administrative Core$156,046
U19 · FY2017 · AI · contact PI
Pilot/Feasibility Studies Program$69,503
U19 · FY2017 · AI · contact PI
Research Training in Digestive Diseases$69,204
T32 · FY2017 · DK · contact PI
Reversal of Immune Failure with Viral Cure in Chronic HCV Infection$2,277,111
U19 · FY2016 · AI · contact PI
HIV-Hepatitis C Virus Cooperative Interactions and Liver Disease Progression$589,282
R01 · FY2016 · DK · contact PI
Research Training in Digestive Diseases$509,417
T32 · FY2016 · DK · contact PI
Restoration of Innate Immunity with Viral Cure$446,236
U19 · FY2016 · AI · contact PI
Harvard Hepatitis B Consortium$366,277
U01 · FY2016 · DK
HIV-Associated Macrophage Alterations and Progressive Liver Disease$325,000
R01 · FY2016 · DK · contact PI
Patient-Oriented Research on Hepatitis in Special Populations$160,354
K24 · FY2016 · DK · contact PI
Administrative Core$148,732
U19 · FY2016 · AI · contact PI
Pilot/Feasibility Studies Program$64,620
U19 · FY2016 · AI · contact PI
Research Training in Digestive Diseases$59,718
T32 · FY2016 · DK · contact PI
Reversal of Immune Failure with Viral Cure in Chronic HCV Infection$2,277,111
U19 · FY2015 · AI · contact PI
HIV-Hepatitis C Virus Cooperative Interactions and Liver Disease Progression$719,784
R01 · FY2015 · DK · contact PI
Discovery and Assessment of Genetic Determinants of HCV and HIV Control$636,115
R01 · FY2015 · DA · contact PI
Research Training in Digestive Diseases$531,377
T32 · FY2015 · DK · contact PI
Harvard Hepatitis B Consortium$508,762
U01 · FY2015 · DK
Restoration of Innate Immunity with Viral Cure$498,302
U19 · FY2015 · AI · contact PI
HIV-Associated Macrophage Alterations and Progressive Liver Disease$325,000
R01 · FY2015 · DK · contact PI
Harvard Hepatitis B Consortium$242,389
U01 · FY2015 · DK
Administrative Core$171,977
U19 · FY2015 · AI · contact PI
Patient-Oriented Research on Hepatitis in Special Populations$160,354
K24 · FY2015 · DK · contact PI
Pilot/Feasibility Studies Program$68,500
U19 · FY2015 · AI · contact PI
Reversal of Immune Failure with Viral Cure in Chronic HCV Infection$2,351,111
U19 · FY2014 · AI · contact PI
HIV-Hepatitis C Virus Cooperative Interactions and Liver Disease Progression$745,882
R01 · FY2014 · DK · contact PI
Discovery and Assessment of Genetic Determinants of HCV and HIV Control$650,016
R01 · FY2014 · DA · contact PI
Research Training in Digestive Diseases$512,907
T32 · FY2014 · DK · contact PI
Restoration of Innate Immunity with Viral Cure$382,133
U19 · FY2014 · AI · contact PI
Harvard Hepatitis B Consortium$324,326
U01 · FY2014 · DK
Development of Gap Junction Inhibition Therapy for Alcoholic Liver Disease$196,305
R43 · FY2014 · AA
Patient-Oriented Research on Hepatitis in Special Populations$160,354
K24 · FY2014 · DK · contact PI
Administrative Core$157,715
U19 · FY2014 · AI · contact PI
Pilot/Feasibility Studies Program$69,290
U19 · FY2014 · AI · contact PI
Research Training in Digestive Diseases$29,890
T32 · FY2014 · DK · contact PI
HIV-Hepatitis C Virus Cooperative Interactions and Liver Disease Progression$26,098
R01 · FY2014 · DK · contact PI
Mechanisms of immune Failure in Chronic Infection: Hepatitis C as a Key Paradigm$2,728,785
U19 · FY2013 · AI · contact PI
Discovery and Assessment of Genetic Determinants of HCV and HIV Control$640,563
R01 · FY2013 · DA · contact PI
HIV-Hepatitis C Virus Cooperative Interactions and Liver Disease Progression$607,782
R01 · FY2013 · DK · contact PI
Research Training in Digestive Diseases$451,466
T32 · FY2013 · DK · contact PI
Harvard Hepatitis B Consortium$412,328
U01 · FY2013 · DK
The Central Role of the Hepatocyte in HCV Persistence$329,939
U19 · FY2013 · AI · contact PI
Pilot/Feasibility Studies Program of the HCV Persistence Study Group (HPSG)$193,404
U19 · FY2013 · AI · contact PI
Administrative Core for the HCV Persistence Study Group (HPSG)$166,724
U19 · FY2013 · AI · contact PI
Patient-Oriented Research on Hepatitis in Special Populations$160,354
K24 · FY2013 · DK · contact PI
Research Training in Digestive Diseases$29,411
T32 · FY2013 · DK · contact PI
Mechanisms of immune Failure in Chronic Infection: Hepatitis C as a Key Paradigm$2,902,971
U19 · FY2012 · AI · contact PI
Discovery and Assessment of Genetic Determinants of HCV and HIV Control$702,924
R01 · FY2012 · DA · contact PI
Research Training in Digestive Diseases$517,201
T32 · FY2012 · DK · contact PI
HIV-Hepatitis C Virus Cooperative Interactions and Liver Disease Progression$506,181
R56 · FY2012 · DK · contact PI
The Central Role of the Hepatocyte in HCV Persistence$350,994
U19 · FY2012 · AI · contact PI
Harvard Hepatitis B Consortium$256,025
U01 · FY2012 · DK
Pilot/Feasibility Studies Program of the HCV Persistence Study Group (HPSG)$205,748
U19 · FY2012 · AI · contact PI
Administrative Core for the HCV Persistence Study Group (HPSG)$177,367
U19 · FY2012 · AI · contact PI
Patient-Oriented Research on Hepatitis in Special Populations$160,354
K24 · FY2012 · DK · contact PI
Research Training in Digestive Diseases$68,072
T32 · FY2012 · DK · contact PI
Mechanisms of immune Failure in Chronic Infection: Hepatitis C as a Key Paradigm$2,874,928
U19 · FY2011 · AI · contact PI
Discovery and Assessment of Genetic Determinants of HCV and HIV Control$725,722
R01 · FY2011 · DA · contact PI
Research Training in Digestive Diseases$504,752
T32 · FY2011 · DK · contact PI
Harvard Hepatitis B Consortium$364,513
U01 · FY2011 · DK
The Central Role of the Hepatocyte in HCV Persistence$304,733
U19 · FY2011 · AI · contact PI
Administrative Core for the HCV Persistence Study Group (HPSG)$231,284
U19 · FY2011 · AI · contact PI
Pilot/Feasibility Studies Program of the HCV Persistence Study Group (HPSG)$195,444
U19 · FY2011 · AI · contact PI
Patient-Oriented Research on Hepatitis in Special Populations$165,243
K24 · FY2011 · DK · contact PI
Research Training in Digestive Diseases$71,419
T32 · FY2011 · DK · contact PI
Mechanisms of immune Failure in Chronic Infection: Hepatitis C as a Key Paradigm$2,987,979
U19 · FY2010 · AI · contact PI
Discovery and Assessment of Genetic Determinants of HCV and HIV Control$837,583
R56 · FY2010 · AI · contact PI
Mechanisms of immune Failure in Chronic Infection: Hepatitis C as a Key Paradigm$464,438
U19 · FY2010 · AI · contact PI
Research Training in Digestive Diseases$374,323
T32 · FY2010 · DK · contact PI
HIV-Hepatitis C Virus Interactions and Pathogenesis$371,317
R01 · FY2010 · AI · contact PI
Harvard Hepatitis B Consortium$329,691
U01 · FY2010 · DK
The Central Role of the Hepatocyte in HCV Persistence$317,206
U19 · FY2010 · AI · contact PI
Serum Apoptosis Markers as Biomarkers in Acute Liver Failure$243,647
R21 · FY2010 · DK · contact PI
Administrative Core for the HCV Persistence Study Group (HPSG)$240,448
U19 · FY2010 · AI · contact PI
Pilot/Feasibility Studies Program of the HCV Persistence Study Group (HPSG)$203,357
U19 · FY2010 · AI · contact PI
Patient-Oriented Research on Hepatitis in Special Populations$164,438
K24 · FY2010 · DK · contact PI
Research Training in Digestive Diseases$65,791
T32 · FY2010 · DK · contact PI
Mechanisms of immune Failure in Chronic Infection: Hepatitis C as a Key Paradigm$3,086,377
U19 · FY2009 · AI · contact PI
HIV-Hepatitis C Virus Interactions and Pathogenesis$375,067
R01 · FY2009 · AI · contact PI
Harvard Hepatitis B Consortium$374,534
U01 · FY2009 · DK
The Central Role of the Hepatocyte in HCV Persistence$327,905
U19 · FY2009 · AI · contact PI
Administrative Core for the HCV Persistence Study Group (HPSG)$250,367
U19 · FY2009 · AI · contact PI
Serum Apoptosis Markers as Biomarkers in Acute Liver Failure$221,016
R21 · FY2009 · DK · contact PI
Pilot/Feasibility Studies Program of the HCV Persistence Study Group (HPSG)$212,901
U19 · FY2009 · AI · contact PI
Patient-Oriented Research on Hepatitis in Special Populations$163,631
K24 · FY2009 · DK · contact PI
HIV-Hepatitis C Virus Interactions and Pathogenesis$375,067
R01 · FY2008 · AI · contact PI
Patient-Oriented Research on Hepatitis in Special Populations$162,825
K24 · FY2008 · DK · contact PI
Harvard Hepatitis B Consortium$129,767
U01 · FY2008 · DK
HIV-Hepatitis C Virus Interactions and Pathogenesis$382,331
R01 · FY2007 · AI · contact PI
Patient-Oriented Research on Hepatitis in Special Populations$162,019
K24 · FY2007 · DK · contact PI
HIV-Hepatitis C Virus Interactions and Pathogenesis$393,750
R01 · FY2006 · AI · contact PI
Chemical Genetics:Cellular Regulators of HCV (RMI)$86,500
R03 · FY2004 · NS
NOVEL ANIMAL MODELS OF HCV-RELATED HEPATOCARCINOGENESIS$304,781
R01 · FY2003 · DK
NOVEL ANIMAL MODELS OF HCV-RELATED HEPATOCARCINOGENESIS$326,513
R01 · FY2002 · DK
NOVEL ANIMAL MODELS OF HCV-RELATED HEPATOCARCINOGENESIS$291,936
R01 · FY2001 · DK
NOVEL ANIMAL MODELS OF HCV-RELATED HEPATOCARCINOGENESIS$30,000
R01 · FY2001 · DK
NOVEL ANIMAL MODELS OF HCV-RELATED HEPATOCARCINOGENESIS$286,514
R01 · FY2000 · DK